Gilead Sciences (GILD) has been under a strong bear grip, hence the stock is down -9.35% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.75% in the past 1 week. The stock has risen by 1.18% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.09% in the past 4 weeks.
Gilead Sciences (NASDAQ:GILD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.20 and $79.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.66. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.41, notching a gain of 0.80% for the day. The total traded volume was 10,692,338 . The stock had closed at $79.77 on the previous day.
The stock has recorded a 20-day Moving Average of 4.4% and the 50-Day Moving Average is 4.43%. Gilead Sciences Inc. has dropped 4.51% during the last 3-month period . Year-to-Date the stock performance stands at -19.7%.
Gilead Sciences (GILD) : Currently there are 13 street experts covering Gilead Sciences (GILD) stock. The most bullish and bearish price target for the stock is $133 and $93 respectively for the short term. The average price target of all the analysts comes to $111.31. The estimated standard deviation from the target is $11.23.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.